GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: P3A | SYN-004
Compound class:
Peptide
Comment: Ribaxamase is an orally delivered β-lactamase enzyme, under clinical development as a protective agent against dysbiosis of the gastrointestinal tract caused by some antibacterial drugs [1]. The peptide sequence for ribaxamase is available from its INN record.
|
| References |
|
1. Kaleko M, Bristol JA, Hubert S, Parsley T, Widmer G, Tzipori S, Subramanian P, Hasan N, Koski P, Kokai-Kun J et al.. (2016)
Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection. Anaerobe, 41: 58-67. [PMID:27262694] |
|
2. Kokai-Kun JF, Roberts T, Coughlin O, Le C, Whalen H, Stevenson R, Wacher VJ, Sliman J. (2019)
Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial. Lancet Infect Dis, 19 (5): 487-496. [PMID:30885591] |
|
3. Kokai-Kun JF, Roberts T, Coughlin O, Sicard E, Rufiange M, Fedorak R, Carter C, Adams MH, Longstreth J, Whalen H et al.. (2017)
The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies. Antimicrob Agents Chemother, 61 (3). [PMID:28052855] |
